In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2024.

Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London.

This episode explores emerging trends in the treatment of valvular heart disease, focussing on TAVI procedures and transcatheter interventions. It also covers recent advancements in pharmacological management for cardiovascular conditions. Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year’s most impactful trials:

EARLY TAVR
RESHAPE 2
MATTERHORN
TRILUMINATE
TOPSPIN
FINEARTS-HF

What are the most impactful cardiovascular trials of 2024? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?

EP 125: Structural Interventions and Emerging Pharmacotherapies: The Year 2024 In Review with Dr Sukh Nijjer

‘Parallax’ (/ˈparəlaks/)-noun: the effect whereby the position or direction of an object appears to differ when viewed from different positions. Join Ankur Kalra, MD as he shows you a different side to cardiovascular care, management and science. Listen to Ankur’s conversations with legendary cardiologists, critical reviews of key congresses and late-breaking trials, and concise summaries. Published every second Monday of the month, this is your fix of reliable updates on all things cardiology by someone from a non-traditional background, who is always trying to look at it from new angles! Dear cardiologists, we want to make this podcast about you, and for you! Please email us critical thoughts, comments and questions for Ankur at podcast@radcliffe-group.com.

New tracks tagged #tavi procedures